Hair Loss Medication: How Each Drug Actually Works
Introduction: Why “FDA-Approved” Isn’t the Same as “Right for Every Patient”
Many people noticing thinning hair assume the next step is simple: start finasteride, start minoxidil, or both. Direct-to-consumer telehealth advertising reinforces that idea, often presenting these two drugs as interchangeable “first options” available after a short online questionnaire.
The reality is more specific than that. Only two medications are FDA-approved for androgenetic alopecia (AGA), the medical term for pattern hair loss. Topical minoxidil is approved for both men and women. Oral finasteride is approved for male pattern hair loss only. Every other medication discussed in hair loss circles is either used off-label or still under investigation.
These medications also do not work the same way. They act at four distinct biological intervention points, and none of them helps unless the underlying diagnosis is actually androgenetic alopecia. AGA is extremely common. According to Medscape’s clinical overview, it affects roughly 50% of men and perhaps as many women older than 40, and it can begin as early as the teenage years. However, shedding has several other causes that can look nearly identical on the surface.
This article treats hair loss medication as a precision tool. Each drug should be matched to a mechanism and a confirmed diagnosis, not chosen by default.
The Diagnostic Prerequisite: Medication Only Works If the Diagnosis Is Androgenetic Alopecia
Every medication covered in this article targets one process: androgen-driven follicular miniaturization. In genetically susceptible follicles, the hormone dihydrotestosterone (DHT) gradually shrinks hair follicles over successive growth cycles. Hairs become finer, shorter, and eventually stop growing visibly.
None of these drugs treats thyroid-related shedding, iron-deficiency shedding, or telogen effluvium. Telogen effluvium is a condition in which a large number of hairs shift into the resting phase at once, often after illness, surgery, childbirth, significant stress, or rapid weight loss. It can produce diffuse thinning that resembles early pattern hair loss, yet it has nothing to do with DHT or androgen receptors. In many cases, it resolves once the trigger is addressed.
Scale makes this distinction important. Approximately 50 million men and 30 million women in the United States have androgenetic alopecia. Because the condition is so common, shedding is often attributed to it by default. That assumption leads to misdiagnosis when another cause is responsible.
What Bloodwork Should Rule Out Before Starting Any Hair Loss Medication
The labs most consistently recommended before or alongside hair loss medication include:
- Ferritin, a measure of the body’s iron stores
- Complete blood count (CBC), which screens for anemia and other blood abnormalities
- Thyroid function (TSH and free T4), which identifies hypothyroidism or hyperthyroidism
These labs do not confirm androgenetic alopecia. Their purpose is to rule out reversible causes that would make medication ineffective or irrelevant. A review in the European Medical Journal notes that labs such as CBC, ferritin, thyroid, and vitamin D levels “can aid in understanding the aetiology of alopecia.”
The practical consequence is significant. If shedding is driven by low iron or an underactive thyroid, finasteride or minoxidil will not correct it. Months spent on the wrong medication delay the actual fix. This is why Shapiro Medical Group’s clinical approach places diagnosis before prescription, not the reverse.
The Four Biological Intervention Points of Hair Loss Medication
The rest of this article is organized around four categories:
- Production inhibition: reducing how much DHT the body makes
- Receptor blockade: preventing DHT from binding at the follicle
- Growth-cycle modulation: altering how long follicles stay in active growth
- Stem-cell reactivation: waking dormant follicle cells (investigational)
These are not redundant alternatives. They intervene at different stages of the same biological story, from hormone synthesis to follicle behavior. Understanding where a drug acts clarifies who it is appropriate for, regardless of how heavily it is advertised.
Intervention Point 1: Inhibiting DHT Production at the Source
The first strategy works upstream. Rather than acting at the follicle, these drugs reduce how much DHT the body produces from testosterone in the first place. They do this by inhibiting 5-alpha-reductase, the enzyme responsible for that conversion.
This approach slows follicular miniaturization. It does not create new follicles, and on its own it does not fully reverse miniaturization that has already occurred.
Finasteride: The Original 5-Alpha-Reductase Inhibitor
Finasteride is a competitive type II 5-alpha-reductase inhibitor. It is FDA-approved for male pattern hair loss only.
Oral finasteride reduces scalp DHT by approximately 60% to 70%, depending on dosage. The American Hair Loss Association cites dose-ranging data showing that 1 mg daily reduced scalp DHT by roughly 64% and serum DHT by roughly 71% after 42 days.
The safety conversation. Post-finasteride syndrome (PFS) describes persistent sexual, physical, and neuropsychiatric symptoms reported by some men after stopping the drug. The topic remains scientifically unresolved. A review in the International Journal of Dermatology states that PFS “remains controversial due to the lack of conclusive evidence substantiating that finasteride is the cause” of these persistent effects.
On one side, the largest placebo-controlled follow-up available, drawn from the Prostate Cancer Prevention Trial and covering 267,983 person-years, found no evidence supporting PFS as a distinct syndrome. On the other side, regulators including the European Medicines Agency (EMA) and the FDA have added suicidality and mood-disorder warnings to labeling following post-marketing reports. The EMA’s 2025 review identified 325 cases of suicidal ideation linked to finasteride in young men treated for hair loss, based on reports in its EudraVigilance database.
These findings do not settle the question in either direction. They do mean that patients deserve a candid discussion of both the reassuring trial data and the regulatory signals before starting treatment.
Finasteride is maintenance, not a cure. Benefits reverse within months to a year of discontinuation. Hair preserved by the drug is typically lost once DHT levels return to baseline.
Dutasteride: A More Potent, Off-Label Alternative
Dutasteride is a dual 5-alpha-reductase inhibitor, blocking both the type I and type II isoenzymes. This broader action makes it more potent than finasteride at lowering DHT.
It is not FDA-approved for hair loss in the United States, although it is approved for this indication in South Korea and Japan. Milligram for milligram, dutasteride is more effective at lowering DHT, and it has produced better hair-count results than finasteride in clinical trials.
Greater potency is not automatically better for every patient. Its off-label US status and stronger systemic effect mean dutasteride calls for more careful clinical judgment. It is a distinct clinical decision, not a simple substitution for finasteride.
Intervention Point 2: Blocking the Androgen Receptor Directly at the Follicle
The second category represents a conceptual shift. Instead of reducing how much DHT exists in the body, these drugs prevent DHT from binding to its receptor at the follicle.
The distinction matters clinically. Receptor blockade can, at least in principle, work locally without altering systemic DHT levels. That changes the side-effect considerations compared with production inhibitors.
Clascoterone (Breezula): A Topical Androgen Receptor Antagonist
Clascoterone, being developed for hair loss under the name Breezula, represents a genuinely new mechanism for this condition. It is a topical androgen receptor antagonist that competes with DHT for receptor binding directly at the follicle.
The key differentiator is that it does not lower systemic DHT. Finasteride and dutasteride reduce DHT throughout the body; clascoterone aims to block its effect only where it is applied.
For candidates concerned about systemic hormonal side effects, this localized approach may prove meaningful. Still, it remains an investigational therapy for hair loss, and its long-term safety and effectiveness profile for this use should be judged on emerging data rather than assumptions.
Spironolactone: A Repurposed Antiandrogen for Female Pattern Hair Loss
Spironolactone was originally developed as an aldosterone antagonist, a medication used for conditions such as high blood pressure and fluid retention. Clinicians later repurposed it for its antiandrogenic effects.
According to a systematic review and meta-analysis on spironolactone in female pattern hair loss, its antiandrogenic effects are believed to stem from its ability to inhibit DHT binding to androgen receptors. Conceptually, this resembles clascoterone, but spironolactone is taken orally and acts systemically.
It is widely used off-label for female pattern hair loss, despite lacking FDA approval for that specific indication. This matters for women, because topical minoxidil is the only FDA-approved option for female pattern hair loss. Off-label antiandrogens like spironolactone are therefore a meaningful but distinct clinical decision, best made with a specialist who understands the hormonal context of each patient.
Intervention Point 3: Modulating the Hair Growth Cycle
Minoxidil is mechanistically distinct from everything above. It does not target DHT or androgen receptors at all.
It is also the least understood mechanism among approved treatments. That fact matters for setting realistic expectations.
Topical Minoxidil: An Incompletely Understood Mechanism
Researchers have not fully explained how minoxidil works. What is well documented is what it does. Through a still-unclear pathway, minoxidil:
- Enlarges miniaturized follicles
- Extends the anagen (growth) phase
- Shortens the telogen (resting) phase
A common misconception is that minoxidil works by increasing blood flow to the scalp. Minoxidil sulfate, its active metabolite, does open ATP-sensitive potassium channels, an action associated with vasodilation. However, current evidence suggests that vasodilation is not the operative mechanism behind hair regrowth.
Topical minoxidil holds a unique regulatory position: it is the only FDA-approved topical medication for hair loss in both men and women.
Low-Dose Oral Minoxidil (LDOM): A Popular Off-Label Shift
Low-dose oral minoxidil has become a mainstream off-label option. Minoxidil tablets were originally developed to treat hypertension, and clinicians now prescribe them at much lower doses for hair loss.
LDOM is not FDA-approved for hair loss at any dose. An important safety nuance is often missing from consumer-facing content: oral minoxidil tablets carry an FDA boxed warning, and that warning has not been removed or modified for low-dose use.
The convenience of a daily pill does not change the underlying profile. Compared with the topical version, LDOM remains off-label and carries systemic considerations that warrant medical evaluation and appropriate monitoring.
Intervention Point 4: Reactivating Dormant Follicle Stem Cells
The fourth category is an entirely different biological strategy. It does not target androgens, receptors, or growth-cycle timing. Instead, it targets cellular dormancy itself.
This category is emerging and investigational. It provides forward-looking context rather than a basis for present-day treatment planning.
PP405: Targeting Mitochondrial Metabolism to Wake Dormant Follicles
PP405, developed by Pelage Pharmaceuticals, is a first-in-class topical mitochondrial pyruvate carrier (MPC) inhibitor. As Dermatology Times describes it, the therapy is designed to reactivate dormant hair follicle stem cells rather than block hormone signaling of any kind.
The concept is that follicles in pattern hair loss may still contain stem cells that have simply stopped activating. By adjusting cellular metabolism, PP405 aims to restart that activity. It is a possible first-in-class drug with a genuinely novel mechanism of action, and it remains in development.
VDPHL01: A Potential New Oral Option on the Horizon
VDPHL01 is an extended-release oral minoxidil formulation in late-stage development. Strictly speaking, it belongs mechanistically with growth-cycle modulators, but it is part of the same pipeline wave.
In April 2026, VDPHL01 hit its Phase 3 primary endpoint, with 79% to 86% of participants reporting improvement versus 36% on placebo. If it progresses toward approval, it could become the first new oral hair loss pill in roughly 30 years.
That claim should stay provisional. Phase 3 success does not equal regulatory approval or availability, and additional review is required before any clinical use outside trials.
A Mechanistically Distinct Category Worth Knowing: JAK Inhibitors and Alopecia Areata
JAK inhibitors, including baricitinib, ritlecitinib, and deuruxolitinib, have been approved for alopecia areata. Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, often causing patchy loss. It is not androgenetic alopecia.
Searchers frequently confuse the two because both fall under the general label “hair loss.” The biology, diagnosis, and treatment pathways are entirely different.
This reinforces the article’s central point: matching mechanism to diagnosis is not optional. A JAK inhibitor will not help AGA, just as finasteride will not help alopecia areata.
Safety Is Mechanism-Specific, Not Universal
Grouping all “hair loss medications” together obscures meaningful differences. Each intervention point carries its own safety profile:
- Production inhibitors (finasteride, dutasteride): The PFS question remains unresolved. Large placebo-controlled data do not support PFS as a distinct syndrome, yet regulators have issued mood and suicidality warnings based on post-marketing reports. Patients should understand both.
- Systemic receptor blockers (spironolactone): These carry hormonal and systemic considerations distinct from topical options, especially relevant for women.
- Oral growth-cycle modulators (LDOM): This is a parallel example of a popular off-label treatment with unresolved systemic risk messaging, given the boxed warning that remains unchanged for low-dose use.
- Investigational agents (clascoterone, PP405, VDPHL01): Their safety profiles for hair loss are still being defined.
One caveat applies across nearly all of these medications: discontinuation reverses benefit. Gains typically regress within months to a year after stopping. These are maintenance tools, not cures.
Why Mechanism-Matching Requires Diagnosis First
The four intervention points only matter once a diagnosis is established. That is why Shapiro Medical Group treats medication selection as one component of a broader diagnostic process. Thyroid dysfunction, low ferritin, and telogen effluvium are ruled out first. Only then does the question of which mechanism, if any, applies come into focus.
This contrasts sharply with many direct-to-consumer telehealth models. Those funnels often work backward: a person searches for a specific drug and is routed toward a prescription for it. A differential diagnosis, by contrast, starts with the question of what is actually causing the hair loss.
Choosing between production inhibition, receptor blockade, growth-cycle modulation, or eventually stem-cell reactivation depends on patient-specific factors, including:
- Sex, since approval status and appropriate options differ for men and women
- Pattern of loss, which helps distinguish AGA from other conditions
- Lab results, which may reveal a reversible cause
- Tolerance for systemic versus local effects, which shapes whether an oral or topical approach makes more sense
For some patients, medication is also part of a longer-term plan that may include surgical or other non-surgical options. Because Shapiro Medical Group’s physicians have focused exclusively on hair restoration since 1990, medication decisions are made with that full picture in view.
Conclusion: Medication as a Precision Tool, Not a Default Step
Hair loss medications act at four distinct points: reducing DHT production, blocking DHT at the receptor, modulating the growth cycle, and, in investigational therapies, reactivating dormant follicle stem cells. Despite common marketing that presents them as interchangeable, they differ in mechanism, approval status, and safety considerations.
None of those mechanisms matters if the underlying condition is not androgenetic alopecia. Medication works best as one calibrated component of a diagnostic process, not as a standalone first move.
Consulting a Specialist Before Starting Any Hair Loss Medication
Anyone experiencing hair loss benefits from a proper diagnostic evaluation before selecting a medication based on advertising. Shapiro Medical Group brings more than three decades of exclusive focus on hair restoration, board-certified physicians, and a diagnostic-first approach to every case. Its team includes Dr. Ron Shapiro, co-author of the textbook physicians call the “Hair Transplant Bible.”
Scheduling a consultation is the appropriate next step. A specialist can determine whether androgenetic alopecia is actually the underlying cause and, if so, which mechanism is best matched to the individual case.
